RT Journal Article
T1 Genome-wide association study in Spanish identifies ADAM metallopeptidase with thrombospondin type 1 motif, 9 (ADAMTS9), as a novel asthma susceptibility gene.
A1 Barreto-Luis, Amalia
A1 Pino-Yanes, Maria
A1 Corrales, Almudena
A1 Campo, Paloma
A1 Callero, Ariel
A1 Acosta-Herrera, Marialbert
A1 Cumplido, Jose
A1 Ma, Shwu-Fan
A1 Martinez-Tadeo, Juan
A1 Villar, Jesus
A1 Garcia, Joe G N
A1 Carrillo, Teresa
A1 Carracedo, Angel
A1 Blanca, Miguel
A1 Flores, Carlos
K1 Genetic Predisposition to Disease
K1 Genome-Wide Association Study
K1 Polymorphism, Single Nucleotide
AB Numerous candidate gene and linkage studies have identified loci associated with asthma susceptibility. Recently, the analysis of single nucleotide polymorphisms (SNPs) from the entire genome through genome-wide association studies (GWASs) has provided new insights into asthma pathogenesis. However, these GWASs have revealed only a handful of firm asthma susceptibility genes, explaining a small proportion of the disease heritability. Genetic risk can vary among different populations, and in previous GWASs, Spanish subjects were poorly represented. We hypothesized that a GWAS of asthma in Spanish subjects examining the comprehensive catalogue of genetic variation from the 1000 Genomes Project could reveal new susceptibility genes. Here, we performed the first GWAS of asthma in a Spanish population using a 3-stage design, analyzing a total of 1180 cases and 1915 control subjects.
PB Elsevier
YR 2015
FD 2015-11-24
LK http://hdl.handle.net/10668/9646
UL http://hdl.handle.net/10668/9646
LA en
NO Barreto-Luis A, Pino-Yanes M, Corrales A, Campo P, Callero A, Acosta-Herrera M, et al. Genome-wide association study in Spanish identifies ADAM metallopeptidase with thrombospondin type 1 motif, 9 (ADAMTS9), as a novel asthma susceptibility gene. J Allergy Clin Immunol. 2016 Mar;137(3):964-6
NO Supported by Instituto de Salud Carlos III (FIS PI11/00623) and cofinanced by the European Regional Development Funds, ‘‘Away of making Europe’’ from the European Union and by a grant from the 7th Framework Programme (FP7-REGPOT-2012CT2012-31637-IMBRAIN). M.A.-H. and A.B.-L. were supported by fellowships from the Instituto de Salud Carlos III (FI11/00074 and FI12/00493, respectively).
DS RISalud
RD Apr 10, 2025